加兰大胺改善了Leprdb/db小鼠的血糖控制和糖尿病病
Qinghe Meng1, Julia Ma1, Liye Suo2
1Department of Surgery, State University of New York (SUNY), Upstate Medical University, 750 E Adams St., Suite 8141, Syracuse, NY, 13210, USA.
Scientific reports
|September 21, 2023
概括
氨酸可以改善血糖控制,并减少糖尿病小鼠的损伤. 这种乙胆酶抑制剂还可以降低炎症和胰岛素抵抗,为代谢综合征和糖尿病病提供潜在的益处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 作为一种乙胆酶抑制剂的加兰大胺显示出抗炎和胰岛素敏感作用.
- 代谢综合征与炎症和胰岛素抵抗有关,增加了糖尿病病等并发症的风险.
研究的目的:
- 在小鼠模型中调查加兰他胺对血糖控制和糖尿病病发作的影响.
- 探索加兰他胺对代谢和脏参数影响的潜在机制.
主要方法:
- 使用Leprdb/db小鼠,作为2型糖尿病和肥胖症的模型.
- 给予的胺和对体重,食物摄入量,血糖,HbA1c,胰岛素抵抗 (HOMA-IR,QUICKI) 和β细胞功能 (HOMA-β) 的评估影响.
- 评估了血炎性细胞因子 (TNF-α,IL-6,HMGB-1),功能标志物 (BUN,肌,白蛋白尿),组织学,亡以及分子通路 (P-38 MAPK,caspase-1,SGLT-2).
主要成果:
- 加兰他胺显著降低了食物摄入量,体重,血糖和HbA1c水平.
- 治疗减弱了胰岛素抵抗,提高了炎症性细胞因子水平,并改善了β细胞功能.
- 加兰他改善了糖尿病引起的损伤,改善了功能,组织学,并减少了亡.
- 这些好处与GLP-1的增加,脏P-38 MAPK和caspase-1激活的减少以及SGLT-2表达的减少有关.
结论:
- 在临床前模型中,Galantamine在改善血糖控制和减轻糖尿病病方面表现出显著的益处.
- 药物的作用包括调节炎症通路,胰岛素抵抗和关键标记物.
- 这些发现表明,加兰他胺是治疗2型糖尿病并发症的潜在治疗剂.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204
01:06Oral Hypoglycemic Agents: Glinides
176
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176
01:24Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348